Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.
We report a patient with squamous cell carcinoma (SQCC) of the lung and a discoid-receptor-2 (DDR2) kinase domain mutation that responded to dasatinib treatment. Our case report is consistent with previous publications suggesting that DDR2 mutation may confer sensitivity to dasatinib.
Department of Medical Oncology, University of Messina, Italy. Electronic address: vpitini@unime.it.
Vincenzo
V
Pitini
Carmela
C
Arrigo
Cristian
C
Di Mirto
Patrizia
P
Mondello
Giuseppe
G
Altavilla
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics; D004252:DNA Mutational Analysis; D000069439:Dasatinib; D000070818:Discoidin Domain Receptors; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics; D008875:Middle Aged; D020125:Mutation, Missense; D009378:Neoplasms, Multiple Primary / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D011859:Radiography; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D011975:Receptors, Mitogen / Q000235:genetics*; D013844:Thiazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011743:Pyrimidines; D011975:Receptors, Mitogen; D013844:Thiazoles; D000070818:Discoidin Domain Receptors; D020794:Receptor Protein-Tyrosine Kinases; D000069439:Dasatinib
Chronic myelogenous leukemia; DDR2; Dasatinib; Driver mutations; Squamous-cell carcinoma; Targeted therapies